Probe-dependent Proximity Profiling (ProPPr) Uncovers Similarities and Differences in Phospho-Tau-Associated Proteomes Between Tauopathies

Dmytro Morderer,Melissa C. Wren,Feilin Liu,Naomi Kouri,Anastasiia Maistrenko,Bilal Khalil,Nora Pobitzer,Michelle Salemi,Brett S. Phinney,Dennis W. Dickson,Melissa E. Murray,Wilfried Rossoll

DOI: https://doi.org/10.1101/2024.03.25.585597

2024-03-28

Abstract:Tauopathies represent a diverse group of neurodegenerative disorders characterized by the abnormal aggregation of the microtubule-associated protein tau. Despite extensive research, the precise mechanisms underlying the complexity of different types of tau pathology remain incompletely understood. Here we describe an approach for proteomic profiling of aggregate-associated proteomes on slides with formalin-fixed, paraffin-embedded (FFPE) tissue that utilizes proximity labelling upon high preservation of aggregate morphology, which permits the profiling of pathological aggregates regardless of their size. To comprehensively investigate the common and unique protein interactors associated with the variety of tau lesions present across different human tauopathies, Alzheimer’s disease (AD), corticobasal degeneration (CBD), Pick’s disease (PiD), and progressive supranuclear palsy (PSP), were selected to represent the major tauopathy diseases. Implementation of our widely applicable Probe-dependent Proximity Profiling (ProPPr) strategy, using the AT8 antibody, permitted identification and quantification of proteins associated with phospho-tau lesions in well-characterized human post-mortem tissue. The analysis revealed both common and disease-specific proteins associated with phospho-tau aggregates, highlighting potential targets for therapeutic intervention and biomarker development. Candidate validation through high-resolution co-immunofluorescence of distinct aggregates across disease and control cases, confirmed the association of retromer complex protein VPS35 with phospho-tau lesions across the studied tauopathies. Furthermore, we discovered disease-specific associations of proteins including ferritin light chain (FTL) and the neuropeptide precursor VGF within distinct pathological lesions. Notably, examination of FTL-positive microglia in CBD astrocytic plaques indicate a potential role for microglial involvement in the pathogenesis of these tau lesions. Our findings provide valuable insights into the proteomic landscape of tauopathies, shedding light on the molecular mechanisms underlying tau pathology. This first comprehensive characterization of tau-associated proteomes across different tauopathies enhances our understanding of disease heterogeneity and provides a resource for future functional investigation, as well as development of targeted therapies and diagnostic biomarkers.

Neuroscience

What problem does this paper attempt to address?

The main purpose of this paper is to reveal the proteomic characteristics associated with phosphorylated tau protein aggregation in different types of tauopathies through a novel method, and to explore the role of these characteristics in disease progression as well as potential therapeutic targets and biomarkers.

Specifically, researchers developed a method called Probe-dependent Proximity Profiling (ProPPr), which allows for proximity labeling on formalin-fixed, paraffin-embedded (FFPE) human brain tissue sections, enabling proteomic analysis of tau protein pathological aggregates of various sizes. They selected four major tauopathies—Alzheimer's Disease (AD), Corticobasal Degeneration (CBD), Pick's Disease (PiD), and Progressive Supranuclear Palsy (PSP)—to characterize the common and unique proteomes associated with phosphorylated tau protein lesions in these diseases.

Through the analysis of post-mortem brain tissue samples from patients with these diseases, the researchers identified and quantified proteins associated with phosphorylated tau protein aggregation. Their findings revealed both general and disease-specific proteins related to phosphorylated tau protein aggregation, which may help to understand the molecular mechanisms of tauopathies and provide valuable insights for the development of future treatments and diagnostic biomarkers for these diseases.

Some key findings mentioned in the study include:
- Validation of the association between the retromer complex protein VPS35 and phosphorylated tau protein lesions in different tauopathies.
- Discovery of disease-specific protein associations, such as the association of Ferritin Light Chain (FTL) and the neuropeptide precursor VGF with specific pathological lesions.
- Observation of FTL-positive microglia in astrocytic plaques in CBD, suggesting that microglia may be involved in the pathogenesis of these tau protein lesions.

In summary, this study enhances our understanding of the heterogeneity of different tauopathies by comprehensively analyzing the proteome associated with phosphorylated tau protein in these diseases, and provides resources for subsequent functional studies as well as the development of targeted therapies and diagnostic tools.